Skip to main content

DGX

Stock

DGX

Stock
Health Care
Diagnostics & Research

Performance overview

DGX Price
Price Chart

Forward-looking statistics

Beta
0.42
Risk
20.89%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees37K
Market cap$15.8B

Fundamentals

Enterprise value$26.6B
Revenue$10.2B
Revenue per employee—
Profit margin8.83%
Debt to equity93.37

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$7.91
Dividend per share$3.20
Revenue per share$91.51
Avg trading volume (30 day)$150M
Avg trading volume (10 day)$150M
Put-call ratio—

Macro factor sensitivity

Growth+1.3
Credit+1.6
Liquidity-1.1
Inflation+0.5
Commodities+0.8
Interest Rates-1.2

Valuation

Dividend yield1.81%
PEG Ratio18.13
Price to sales1.94
P/E Ratio18.13
Enterprise Value to Revenue2.61
Price to book2.86

Upcoming events

Next earnings dayApril 22, 2025
Next dividend day—
Ex. dividend dayJuly 7, 2025

News

Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?

DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.

Zacks Investment Research (July 7, 2025)
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space

An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.

Zacks Investment Research (July 2, 2025)
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.

Benzinga (April 23, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free